Population Pharmacokinetic Modelling to Assess the Drug- Drug Interactions between Voriconazole and Ruxolitinib

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100042673

Enrollment

Unknown

Registered

2021-01-26

Start date

2021-01-18

Completion date

Unknown

Last updated

2021-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graft versus host disease

Interventions

experimental group:Take 5mg ruxolitinib orally

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients between the ages of 18 and 60 who will have a malignant hematopoietic stem cell transplant.

Exclusion criteria

Exclusion criteria: Patients who are not tolerable to voriconazole or ruxolitinib.

Design outcomes

Primary

Measure	Time frame
Plasma concentration of Ruxolitinib;Plasma concentration of Voriconazole;	—

Countries

China

Contacts

Public ContactDaihong Liu

Department of Hematology, the Fifth Medical Center of Chinese PLA General Hospital

daihongrm@163.com+86 18301339032

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026